What one share of Beam Therapeutics holds
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.
Beam Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.51 |
|---|---|
| Profit | −$0.84 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | −$3.61 |
| Cash and investments | $11.16 |
| Debt | $0.97 |
| Book value | $10.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$14.05 | $1.93 | −$13.04 | — | −$27.45 |
| 2020 | — | −$4.19 | $0.35 | −$2.40 | — | $4.29 |
| 2021 | $0.81 | −$5.77 | $0.73 | −$1.76 | — | $12.09 |
| 2022 | $0.87 | −$4.13 | $0.70 | −$0.38 | — | $10.29 |
| 2023 | $4.90 | −$1.72 | $0.44 | −$2.37 | — | $12.02 |
| 2024 | $0.77 | −$4.58 | $0.11 | −$4.33 | — | $8.77 |
| 2025 | $1.41 | −$0.81 | $0.15 | −$3.64 | — | $12.17 |
Common questions about Beam Therapeutics
How much does one share of Beam Therapeutics earn?
Over the last 12 months, Beam Therapeutics lost $0.84 for each share on $1.51 of sales.
Does Beam Therapeutics pay a dividend?
Beam Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Beam Therapeutics’s book value per share?
Beam Therapeutics’s book value is $10.34 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Beam Therapeutics have?
Each share of Beam Therapeutics has $11.16 of cash and investments and $0.97 of debt, as of June 30, 2026.
What is Beam Therapeutics’s free cash flow per share?
−$3.61 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Beam Therapeutics bought back shares?
Beam Therapeutics’s share count rose about 1426% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.